Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 5, 2014, Pages 308-323

  Ortega, Nancy ^a   Dona I ^b   Moreno, E ^c   Audicana, M T ^d   Barasona, M J ^e   Berges Gimeno, M P ^f   Blanca Lopez, N ^g   Lobera, T ^h   Padial, A ⁱ   Rosado, A ^j   Torres, M J ^b  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL TXAGORRITXU   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^h Allergy Service   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

more..

Author keywords

Acetylsalicylic acid; Algorithm; Diagnosis; Hypersensitivity; Idiosyncrasy; Intolerance; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

GAMMA INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ASTHMA; CASE CONTROL STUDY; DISEASE PREDISPOSITION; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; META ANALYSIS; SENSITIVITY ANALYSIS; ALGORITHM; DRUG HYPERSENSITIVITY; PRACTICE GUIDELINE; REVIEW; SKIN TEST;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG HYPERSENSITIVITY; HUMANS; PRACTICE GUIDELINES AS TOPIC; SKIN TESTS;

EID: 84907998047     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (195)

1. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-6.
2. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wüthrich B; EAACI (the European Academy of Allergology and Clinical Immunology) nomenclature task force. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56:813-24.
3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-6.
4. Anderson JA, Adkinson NF Jr. Allergic reactions to drugs and biologic agents. JAMA. 1987;258:2891-9.
5. Doña I, Blanca-Lopez N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, Rosado A, Rondón C, Campo P, Agúdez JA, Blanca M, Canto G. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011;41:86-95.
6. Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to Aspirin and Nonsteroidal Anti-Inflammatory Drugs. In: Adkinson, Busse, Bochner, Holgate, Simons&Lemanske, editors. Middleton's Allergy 7th Edition. Mosby Elsevier; 2009: p. 1227-43.
7. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87:177-80.
8. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, Brockow K, Campo P, Celik G, Cernadas J, Cortellini G, Gomes E, Niżankowska-Mogilnicka E, Romano A, Szczeklik A, Testi S, Torres MJ, Wöhrl S, Makowska J. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal antiinflammatory drugs. Allergy. 2013;68:1219-32.
9. Ortega N. Quiralte J, Fraj J, Palacios L. Reacciones adversas a los AINE: alergia, intolerancia. In: Pelàez, Dávila, editor. Tratado Alergología. Ergón; 2007: p. 1461-81.
10. Doña I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nuñez I, Gómez F, Salas M, Rondon C, Canto MG, Blanca M. Drug hypersensitivity reactions: patterns of responses, drug involved and temporal variation in a large series of patients evaluated. J Investig Allergy Clin Immunol. 2012;22:363-71.
11. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy. 1980;35:149-54.
12. Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy. 2004;34:1597-601.
13. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002;57:569-74.
14. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U, Malolepszy J, Szczeklik A. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003;58:1064-6.
15. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328:434.
16. Kim JE, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J. 2007;86:396-9.
17. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol. 2002;3:599-607.
18. Erbagci Z. Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J Dermatol. 2004;31:376-82.
19. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004;24:491-505.
20. Asero R. Multiple sensitivity to NSAID. Allergy. 2000;55(9):893-4.
21. Van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol. 1993;35:400-8.
22. Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003;24:137-48.
23. Kemp SF, Lockey RF, Wolf BL, Lieberman P. Anaphylaxis. A review of 266 cases. Arch Intern Med. 1995;155:1749-54.
24. Mullins RJ. Anaphylaxis: risk factors for recurrence. Clin Exp Allergy. 2003;33:1033-40.
25. Cianferoni A, Novembre E, Mugnaini L, Lombardi E, Bernardini R, Pucci N, Vierucci A. Clinical features of acute anaphylaxis in patients admitted to a university hospital: an 11-year retrospective review (1985-1996). Ann Allergy Asthma Immunol. 2001;87:27-32.
26. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Different risks for NSAID-induced anaphylaxis. Ann Pharmacother. 2002;36:24-9.
27. Van der Klauw MM, Wilson JH, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974-1994) and review of the literature. Clin Exp Allergy. 1996;26:1355-63.
28. Asero R. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy. 2005;35:713-6.
29. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30:2234-40.
30. Farooque SP, Lee TH. Aspirin-sensitive respiratory disease. Annu Rev Physiol. 2009;71:465-87.
31. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002;347:1493-9.
32. Celik G, Bavbek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy. 2001;31:1615-22.
33. Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM, Sala A, Folco GC, Bianco S, Robuschi M. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1996;153:572-5.
34. Corrigan CJ, Napoli RL, Meng Q, Fang C, Wu H, Tochiki K, Reay V, Lee TH, Ying S. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma. J Allergy Clin Immunol. 2012;129:1636-46.
35. Wang XS, Wu AY, Leung PS, Lau HY. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease. Allergy. 2007;62:620-7.
36. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J. 1990;3:588-93.
37. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med. 1991;143:1025-9.
38. Campo P, Ayuso P, Salas M, Plaza MC, Cornejo-García JA, Doña I, Torres MJ, Blanca-López N, Canto G, Guéant JL, Sanak M, Blanca M. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy. 2013 doi: 10.1111/all.12187. [Epub ahead of print]
39. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam BK, Penrose JF, Austen FK, Holgate ST, Sampson AP. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Allergy Clin Immunol. 1998;101:834-46.
40. Adamjee J, Suh YJ, Park HS, Choi JH, Penrose JF, Lam BK, Austen KF, Cazaly AM, Wilson SJ, Sampson AP. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol. 2006;209:392-9.
41. Szczeklik A, Nizankowska E, Dworski R. Choline magnesium trisalicylate in patients with aspirin-induced asthma. Eur Respir J. 1990;3:535-9.
42. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirinintolerant asthma. Am J Respir Cell Mol Biol. 2000;23:290-6.
43. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med. 1996;153:567-71.
44. Kim SH, Park HS. Genetic markers for differentiating aspirinhypersensitivity. Yonsei Med J. 2006;47:15-21.
45. Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2010;10:280-90.
46. Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy. 2009;64:823-39.
47. Torres-Galván MJ, Ortega N, Sánchez-García F, Blanco C, Carrillo T, Quiralte J. LTC4-synthase A-444C polymorphism: lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol. 2001;87:506-10.
48. Kim SH, Choi JH, Holloway JW, Suh CH, Nahm DH, Ha EH, Park CS, Park HS. Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. J Korean Med Sci. 2005:20:926-31.
49. Kim SH, Oh JM, Kim YS, Palmer LJ, Suh CH, Nahm DH, Park HS. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy. 2006;36:433-9.
50. Choi JH, Park HS, Oh HB, Lee JH, Suh YJ, Park CS, Shin HD. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet. 2004;114:337-44.
51. Kim SH, Yang EM, Park HJ, Ye YM, Lee HY, Park HS. Differential contribution of the CyslTR1 in patients with aspirin hypersensitivity. J Clin Immunol. 2007;27:613-9.
52. Park JS, Chang HS, Park CS, Lee JH, Lee YM, Choi JH, Park HS, Kim LH, Park BL, Choi YH, Shin HD. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics. 2005;15:483-92.
53. Jinnai N, Sakagami T, Sekigawa T, Kakihara M, Nakajima T, Yoshida K, Goto S, Hasegawa T, Koshino T, Hasegawa Y, Inoue H, Suzuki N, Sano Y, Inoue I. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet. 2004;13:3203-17.
54. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004;113:771-5.
55. Setkowicz M, Mastalerz L, Podolec-Rubis M, Sanak M, Szczeklik A. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol. 2009;123:174-8.
56. Asero R. Predictive value of autologous plasma skin test for multiple nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol. 2007;144:226-30.
57. Asero R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol. 1999;82:554-8.
58. Cornejo-García JA, Jagemann LR, Blanca-López N, Doña I, Flores C, Guéant-Rodríguez RM, Torres MJ, Fernández J, Laguna JJ, Rosado A, Agúndez JA, García-Martín E, Canto G, Guéant JL, Blanca M. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clin Exp Allergy. 2012;42:1772-81.
59. Ayuso P, Cornejo-García JA, Blanca M, Torres MJ, Doña I, Salas M, Blanca-López N, Canto G, Rondon C, Campo P, Laguna JJ, Fernández J, Martínez C, García-Martín E. The diamine oxidase gene is associated with hypersensitivity response to non-steroidal anti-inflammatory drugs. PLoS One. 2012;7(11):e47571.
60. Doña I, Blanca-Lopez N, Torres MJ, Gomez F, Fernandez J, Zambonino MA, Monteseirin FJ, Canto G, Blanca M, Cornejo-Garcıa JA. NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy. 2014;69:438-44.
61. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, Ebner H, Ebner C. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol. 2003;111:882-8.
62. Gómez E, Blanca-López N, Torres MJ, Requena G, Rondon C, Canto G, Blanca M, Mayorga C. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy. 2009;39:1217-24.
63. Canto MG, Andreu I, Fernandez J, Blanca M. Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol. 2009;9:293-7.
64. Quiralte J, Blanco C, Delgado J, Ortega N, Alcantara M, Carrillo R. Challenge-based clinical patterns of 223 Spanish patients with non-steroidal anti-inflammatory drug-induced reactions. J Investig Allergol Clin Immunol. 2007;17:182-8.
65. Kowalski ML, Woszczek G, Bienkiewicz B, Mis M. Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy. 1998;28:1153-8.
66. Carmona MJ, Blanca M, Garcia A, Fernandez S, Burgos F, Miranda A, Vega JM, Garcia J. Intolerance to piroxicam in patients with adverse reactions to nonsteroidal antiinflammatory drugs. J Allergy Clin Immunol. 1992;90:873-9.
67. Harrer A, Lang R, Grims R, Braitsch M, Hawranek T, Aberer W, Vogel L, Schmid W, Ferreira F, Himly M. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PLoS One. 2010;5:e13707.
68. Kvedariene V, Bencherioua AM, Messaad D, Godard P, Bousquet J, Demoly P. The accuracy of the diagnosis of suspected paracetamol (acetaminophen) hypersensitivity: results of a single-blinded trial. Clin Exp Allergy. 2002;32:1366-9.
69. Vidal C, Pérez-Carral C, González-Quintela A. Paracetamol (acetaminophen) hypersensitivity. Ann Allergy Asthma Immunol. 1997;79:320-1.
70. Klote MM, Smith LJ. A case of anaphylaxis to naproxen. Allergy. 2005;60:260-1.
71. Schuster C, Wüthrich B. Anaphylactic drug reaction to celecoxib and sulfamethoxazole: cross reactivity or coincidence? Allergy. 2003;58:1072.
72. Fontaine C, Bousquet PJ, Demoly P. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol. 2005;115:633-4.
73. Figueroa J, Ortega N, Almeida L, Blanco C, Castillo R. Sulfonamide allergy without cross-reactivity to celecoxib. Allergy. 2007;62(1):93.
74. Vidal C, Porras-Hurtado L, Cruz R, Quiralte J, Cardona V, Colas C, Castillo LF, Marcos C, Soto T, Lopez-Abad R, Hernandez D, Audícana MT, Armisen M, Rodríguez V, Perez Carral C, Moreno E, Cabañes R, Corominas M, Parra A, Lobera T, Quiñones D, Ojeda P, Luna I, Torres M, Carracedo A. Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 2013;132(4):989-91
75. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions- new concepts. Clin Exp Allergy. 2007;37:989-9.
76. Bernedo N, Audicana MT, Uriel O, Velasco M, Gaztaminza G, Fernandez E, Muñoz D. Metamizol as a cause of postoperative erythroderma. Contact Dermatitis. 2004;50:317-8.
77. Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T. Intolerance to non-steroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996;98:678-85.
78. Quiralte J, Torres MJ. Aspectos genéticos de la intolerancia a AINES y su correlación clínica. Allergol Immunol Clin. 2000;15:50-5.
79. Quiralte J, Blanco C, Castillo R, Ortega N, Carrillo T. Anaphylactoid reaction due to nonsteroidal anti-inflammatory drugs: clinical and cross-reactivity studies. Ann Allergy Asthma Immunol. 1997;78:293-6.
80. Bochenek G, Nizankowska E, Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal antiinflammatory drugs. Allergy. 1996;51:16-23.
81. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000;84:101-6.
82. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin on aspirin-induced asthma and asthma and rhinitis reactions. Clin Exp Allergy. 2002;32:1491-6.
83. Kupczyk M, Kuprys I, Gorski P, Kuna P. Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma. Ann Allergy Asthma Immunol. 2004;92:453-8.
84. Dávila I, Rondón C, Navarro A, Antón E, Colás C, Dordal MT, Ibáñez MD, Fernández-Parra B, Lluch-Bernal M, Matheu V, Montoro J, Sánchez MC, Valero A. Aeroallergen sensitization influences quality of life and comorbidities in patients with nasal polyposis. Am J Rhinol Allergy. 2012;26(5):e126-31.
85. Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol. 2003;28:123-7.
86. Quiralte J, López-Pascual E, Palacios L, Saenz de San Pedro B, Navarrete MA, Florido F. Una propuesta de clasificación de las reacciones idiosincrásicas a fármacos antiinflamatorios no esteroideos. Alergol Inmunol Clin. 2004;19:185-94.
87. Capriles-Behrens E, Caplin J, Sanchez-Borges M. NSAID facial angioedema in select pediatric atopic population. J Investig Allergol Clin Immunol. 2000;10:277-9.
88. Gómez F, Doña I, Blanca-López N, Torres MJ, Salas M, Rondon C, Campo P, Posadas T, Guerrero MA, Canto G, Blanca M. Food Allergy Is Not A Risk Factor in Cross-Intolerance to NSAIDs for Induction of Symptoms. J Allergy Clin Immunol. 2013;131(2):AB167
89. Quiralte J. Aspirin-induced isolated periorbital angioedema. Ann Allergy Asthma Immunol. 1998;81:459.
90. Blanco C, Quiralte J, Castillo R, Delgado J, Arteaga C, Barber D, Carrillo T. Anaphylaxis after ingestion of wheat flour contaminated with mites. J Allergy Clin Immunol. 1997;99:308-13.
91. Del Pozo MD, Lobera T, Blasco A. Selective hypersensitivity to diclofenac. Allergy. 2000;55:412-3.
92. Patriarca G, Venuti A, Bonini W. Allergy to pyramidon (aminopyrine). Ann Allergy. 1973;31:84-6.
93. Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewics J, Poniatowska M. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc. 1999;20:347-52.
94. Sanchez-Borges M, Capriles-Hulett A. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005;4:837-48.
95. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74:430.
96. Titchen T, Cranswick N, Beggs S. Adverse drug reactions to non-steroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol. 2005;59:718-23.
97. Macias E, Ruiz A, Moreno E, Laffond E, Davila I, Lorente F. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy. 2007;62(12):462-4.
98. Savin JA. Current causes of fixed drug eruption in the UK. Br J Dermatol. 2001;145:667-8.
99. Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, Machet L, Amsler E, Claeys A, Sassolas B, Leroy D, Grange A, Dupuy A, Cordel N, Bonnetblanc JM, Milpied B, Doutre MS, Guinnepain MT, Barbaud A, Chosidow O, Roujeau JC, Lebrun-Vignes B, Descamps V. A three-yearanalysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20:461-4.
100. Bellini V, Stingeni L, Lisi P. Multifocal fixed drug eruption due to celecoxib. Dermatitis. 2009;20:174-6.
101. Niesvaara D, Ortega Rodríguez N, Hernandez HR, Suarez R, Castillo Sainz C, Carrillo Diaz T, Suarez Lorenzo I. Exantema fijo medicamentoso multiple en paciente con intolerancia a los AINEs. J Investig Allergol Clin Immunol. 2011;21(4):201.
102. Nettis E, Giordano D, Colanardi MC, Paradiso MT, Ferrannini A, Tursi A. Delayed-type hypersensitivity rash from ibuprofen. Allergy. 2003;58:539-40.
103. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assement of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.
104. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous hypersensitivity reactions to inhibitors of cyclooxygenase-2. Results of 307 oral provocation tests and review of the literature. Allergy Clin Immunol Int. 2007;19:44-9.
105. Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to non-steroidal anti-inflammatory drugs: A review of the literature. Am J Health Syst Pharm. 2010;67:206-13.
106. Yesudian PD, Penny M, Azurdia RM, King CM. Ibuprofeninduced acute generalized exanthematous pustulosis. Int J Dermatol. 2004;43:208-10.
107. Gonzalo-Garijo MA, Pérez-Calderón R, De Argila D, Rodríguez-Nevado I. Metamizole-induced acute generalized exanthematous pustulosis. Contact Derm. 2003;49:47-8.
108. De Coninck AL, Van Strubarq AS, Pipeleers-Marichal MA, Huyghens LP, Suys ET, Roseeuw DI. Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances. Dermatology. 1996;193:338-41.
109. Mäkelä L, Lammintausta K. Etoricoxib-induced acute generalized exanthematous pustulosis. Acta Derm Venereol. 2008;88:200-1.
110. Brandao FM, Goossens A, Tosti A. Topical drugs. In: Rycroft RJG, Menné T, Frosch PJ, Lepoittevin, eds. Textbook of Contact Dermatitis. 3rd ed. Berlin: Springer-Verlag; 2001. p. 689-723.
111. Barbaud A. Contact dermatitis due to topical drugs. G Ital Dermatol Venereol. 2009;144:527-36.
112. White IR. Phototoxic and Photoallergic Reactions. In: Rycroft RJG, Menné T, Frosch PJ, Lepoittevin, eds. Textbook of Contact Dermatitis. 3rd ed. Berlin: Springer-Verlag; 2001.p. 367-79.
113. Ophaswongse S, Maibach H. Topical nonsteroidal antiinflammatory drugs: allergic and Photoallergic contact dermatitis and phototoxicity. Contact Dermatitis. 1993;29:57-64.
114. Weber JC, Essigman WK. Pulmonary alveolitis and NSAIDsfactor or fiction? Br J Rheumatol. 1986;25:5-6.
115. Esteve JB, Launay-Vacher V, Brocheriou I, Grimaldi A, Izzedine H. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol. 2005;63;385-9.
116. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal anti-inflammatory drugs. Evidence of a common mechanism. Br J Clin Pharmacol. 1999;47:203-10.
117. Ashwath ML, Katner HP. Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib. Postgrad Med J. 2003;79:295-6.
118. Blanca-López N, Doña I, Torres M, Campo P, Rondón C, Seoane ME, Salas M, Canto G, Blanca M. Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-intolerance. Clin Exp Allergy. 2013;43:85-91.
119. Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, Kondoh A, Arakawa M, Yoshizawa H, Gejyo F. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology. 2005;10:477-84.
120. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16:432-6.
121. Lumry WR, Mathison DA, Stevenson DD. Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitization. J Allergy Clin Immunol. 1982;69:135-43.
122. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, González G, Diéguez I, De Weck AL. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy. 2003;58:312-7.
123. De Paramo BG, Gancedo SQ, Cuevas M, Camo IP, Martin JA, Cosmes EL. Paracetamol (acetaminophen) hypersensitivity. Ann Allergy Asthma Immunol. 2000;85:508-11.
124. Whittam LR, Wakelin SH, Barker JN. Generalized pustular psoriasis or drug-induced toxic pustuloderma? The use of patch testing. Clin Exp Dermatol. 2000;25:122-4.
125. Zedlitz S, Linzbach L, Kauffmann R, Boehncke WH. Reproducible identification of the causative drug of a fixed drug eruption by oral provocation and lesional patch testing. Contact Dermatitis. 2002;46:352-3.
126. Hassan T, Jansen CT. Photopatch test reactivity: effect of photoallergen concentration and UVA dosaging. Contact Dermatitis. 1996;34:383-6.
127. Mewes T, Riechelmann H, Klimek L. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance. Allergy 1996;51:506-10.
128. Kubota Y, Imayama S, Toshitani T, Uemura Y, Koga T, Sugawara N, Kurimoto F, Hata K. Sulfidoleukotriene release test (CAST) in hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol. 1997;114:361-6.
129. Pierzchalska M, Mastalerz L, Sanak M, Zazula M, Szczeklik A. A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leucocytes precludes its value for aspirin sensitivity testing in asthma. Clin Exp Allergy. 2000;30:1785-91.
130. De Weck AL, Sanz ML, Gamboa PM, Aberer W, Blanca M, Correia S, Erdman S, Jermann JM, Kanny G, Kowalski M, Mayorga L, Medrala W, Merk A, Sturm GJ, Sainte-Laudy J, Schneider MS, Sczczeklik A, Weber JM, Wedi A. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. Clinical findings and in vitro diagnosis. J Investig Allergol Clin Immunol. 2009;19:355-69.
131. De Weck AL. Cellular Allergen Stimulation Test (CAST) 2003: a review. J Invest Allergol Clin Immunol. 2004;14:253-73.
132. Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antepara I, Esparza R, de Weck AL. The flow-cytometric determination of basophil activation induced by aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy. 2004;34:1448-57.
133. Celik GE, Schroeder JT, Hamilton RG, Saini SS, Adkinson NF. Effect of in vitro aspirin stimulation on basophils in patients with aspirin exacerbated respiratory disease. Clin Exp Allergy. 2009;39:1522-31.
134. Sanz ML, Gamboa P, De Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs. Int Arch Allergy Immunol. 2005;136:58-72.
135. Sanz ML, Gamboa PM. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2010;40:520-1.
136. Rubio M, Herrero T, De Barrio M. Alergia a pirazolonas. Allergol Immunopathol.1994;22:104-6.
137. Blanca M, Perez E, Garcia J., Miranda A, Terrados S, Vega JM, Suau R. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy. 1989;62:295-8.
138. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59:809-20.
139. Stevenson DD. Diagnosis, prevention and treatment of adverse reactions to aspirin and non-steroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1984;74:617-22.
140. Stevenson DD, Mathison DA. Aspirin sensitivity in asthmatics: when may this drug be safe? Posgrad Med. 1985;78:111-3.
141. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirinsensitive asthma. J Allergy Clin Immunol. 1998;101:581-6.
142. Alonso-Llamazares A, Martinez-Cócera C, Domínguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy. 2002;57:632-5.
143. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wöhrl S, Dahlén B, Szczeklik A. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62:1111-8.
144. Phillips GD, Foord BM, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive asthma: its repeatability, absence of a late phase reaction, and the role of histamine. J Allergy Clin Immunol. 1989;84:232-41.
145. Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation test with aspirin for diagnosis of aspirin-induced asthma. Eur Resp J. 2000;15:863-9.
146. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax. 2000;55:921-4.
147. Alonso-Llamazares A, Rosado A, Vives R. Test de provocación bronquial y nasal con acetilsalicilato de lisina en el diagnóstico de Intolerancia a AINE. Alergol Inmunol Clin. 2002;17:168-74.
148. Melillo G, Padovano A, Cocco G, Masi C. Dosimeter inhalation with lysine acetyl-salicylate for the detection of aspirininduced asthma. Ann Asthma Allergy Immunol. 1993;71:61-5.
149. Park HS. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy. 1993;25:38-40.
150. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, Simon RA, Wald J, Woessner KM; Aspirin Desensitization Joint Task Force. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98:172-4.
151. Gamboa PM. Alergia a los medicamentos. In: Alergológica 2005. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España en Primera edición. Madrid: Luzán. 2005. p. 255-82.
152. Torres MJ, Blanca M, Fernández J, Romano A, Weck A, Aberer W, Brockow K, Pichler WJ, Demoly P; ENDA; EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy. 2003;58:961-72.
153. Ponvert C, Le Clainche L, Blic J, Le Bourgeois M, Scheinmann P, Paupe J. Allergy to beta-lactam antibiotics in children. Pediatrics. 1999;104:1-9.
154. Botey J, Ibero M, Malet A, Marin A, Eseverri JL. Aspirin-induced recurrent urticaria and recurrent angioedema in non-atopic children. Ann Allergy. 1984:53:265-7.
155. Capriles-Behrens E, Caplin J, Sanchez-Borges M. NSAID facial angioedema in a selected pediatric atopic population. J Invest Allergol Clin Immunol. 2000:10:277-9.
156. Botey J, Navarro C, Aulesa C, Marin A, Eseverri JL. Acetyl salicylic acid-induced urticaria and/or angioedema in atopic children. Allergol Immunopathol. 1988:16:43-7.
157. Diaz-Jara M, Perez-Montero A, Gracia-Bara MT, Cabrerizo S, Zapatero L, Martinez-Molero MI. Allergic reactions due to ibuprofen in children. Pediatr Dermatol. 2001;18:66-7.
158. Hassani A, Ponvert C, Karila C, Le Bourgeois M, De Blic J, Scheinmann P. Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases. Eur J Dermatol. 2008;18:561-5.
159. Benahmed S, Picot MC, Dumas F, Demoly P. Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med. 2005;165:1500-5.
160. Kidon MI, Kang LW, Chin CW, Hoon LS, Hugo VB. Nonsteroidal anti inflammatory drug hypersensitivity in preschool children. Allergy Asthma Clin Immunol. 2007;3:114-22.
161. Zambonino MA, Torres MJ, Muñoz C, Requena G, Mayorga C, Posadas T, Urda A, Blanca M, Corzo JL. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol. 2013;2:151-9.
162. Kidon MI, Kang LW, Chin CW, Hoon LS, See Y, Goh A, Lin JT, Chay OM. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. Pediatrics. 2005;116:675-80.
163. Pastorello EA, Zara C, Riario-Sforza GG, Pravettoni V, Incorvaia C. Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy. 1998;53:880-4.
164. Corzo JL, Zambonino MA, Muñoz C, Mayorga C, Requena G, Urda A, Gallego C, Blanca M, Torres MJ. Tolerance to COX-2 inhibitors in children with hypersensitivity to non-steroidal anti-inflammatory drugs. Br J Dermatol. 2014;170(3):275-9.
165. Ortega N, Castillo R, Blanco C, Carrillo T. Nimesulide and rofecoxib tolerance in patients with allergy to nonsteroidal antiinflammatory drugs. Recent Res Del Allergy, Asthma & Immunol 1, Transworld Research Network. India. 2001. p.121-8.
166. Ortega N, Torres MJ, Almeida L, Navarro L, Carrillo T. Tolerancia a los nuevos inhibidores de la COX-2 en el asma y urticaria angioedema con intolerancia a los AINES. Alergol Inmunol Clin. 2002;17(2):30-34.
167. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773-86.
168. Kowalski ML, Makowska J. Use of nonsteroidal antiinflammatory drugs in patients with aspirin hypersensitivity: safety of cyclo-oxygenase-2 inhibitors. Treat Respir Med. 2006;5(6):399-406.
169. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol. 2001;87:72-3.
170. Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A. Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria. J Allergy Clin Immunol. 2006;118(4):957-8.
171. Muñoz-Cano R, Bartra J, Vennera MC, Valero A, Picado C. Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma. J Investig Allergol Clin Immunol. 2009;19:75-6.
172. Passero M, Chowdhry S. Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma. Chest. 2003;123(6):2155-6.
173. Woessner KM, Simon RA, Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2004;93(4):339-44.
174. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118:801-4.
175. Berges-Gimeno MP, Simon RA, Stevenson DD. Long term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;11:180-6.
176. White AA, Hope AP, Stevenson DD. Failure to maintain an aspirin-desensitized state in a patient with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97:446-8.
177. Rothe T, Acherman R, Hug J, Karrer W. Incomplete aspirin desensitization in an aspirin-sensitive asthmatic. Int Arch Allergy Immunol. 1996;109:298-300.
178. Dankner RE, Wedner HJ. Aspirin desensitization in aspirinsensitive asthma: failure to maintain a desensitized state during prolonged therapy. Am Rev Respir Dis. 1983;128;953-5.
179. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E Jr, Ellis EF, Yunginger JW, Reed CE, Adkinson NF Jr, Busse WW, editor. Allergy: principles and practice. 5th ed. Vol 2. St Louis: Mosby; 1998. p.1225-34.
180. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;95:330-5.
181. Patriarca G, Bellioni P, Nucera E, Schiavino D, Papa G, Schinco G, Fais G, Pirotta LR. Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy. 1991;67:588-92.
182. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirinsensitive nasal polyposis: a controlled trial. Laryngoscope. 2005;115:1385-90.
183. Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirinintolerant asthma. J Laryngol Otol. 2007;121:1556-60.
184. Stevenson DD. Aspirin Sensitivity and Desensitization for asthma and sinusitis. Curr Allergy Asthma Rep. 2009;9:155-63.
185. Dalmau G, Gaig P, Gázquez V, Mercé J. Rapid desensitization to acetylsalicylic acid in acute coronary syndrome patients with NSAIDs intolerance. Rev Esp Cardiol. 2009;62:224-30.
186. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirinexacerbated respiratory disease. J Allergy Clin Immunol. 2007;119:157-64.
187. White AA, Stevenson DD. Side effects from daily treatment in patients with AERD: Identification and management. Allergy Asthma Proc. 2011;32:333-4.
188. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. J Allergy Clin Immunol. 2011;3:3-10.
189. Berges-Gimeno MP, Simon RA, Stevenson DD. Long term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;11:180-6.
190. Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am. 2009;29:669-75.
191. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirinsensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996;98:751-8.
192. Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization treatment for aspirin sensitive rhinosinusitis/asthma. J Allergy Clin Immunol. 1990;85:59-65.
193. Forer B, Kivity S, Sade J, Landsberg R. Aspirin desensitization for ASA triad patients – a prospective study of the rhinologist’s perspective. Rhinology. 2011;49;95-100.
194. Wong JT, Nagy CS, Krinzman SJ, Mac Lean JA, Blosch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000;105:997-1001.
195. Mathison DA, Lumry WR, Stevenson DD, Curd JG. Aspirin in chronic urticaria and/or angioedema: Studies of sensitivity and desensitization. J Allergy Clin Immunol. 1982;69:135.